Palliative Cranial Radiotherapy in a Patient With Brain Metastases and Poor Performance Status
A 63-year-old man with metastatic non-small cell lung cancer has 6 brain metastases (largest 2.8 cm) and a KPS of 60. He has mild confusion but is ambulatory and lives with his daughter. He completed chemotherapy 3 weeks ago and has stable extracranial disease. The team debates whole-brain radiotherapy (WBRT) versus stereotactic radiosurgery (SRS) versus hippocampal-avoidance WBRT with memantine. The largest lesion is in the left parietal lobe and is causing mild right-sided weakness. The radiation oncologist must choose a strategy and explain the trade-offs to the family.
1. Compare WBRT, SRS, and hippocampal-avoidance WBRT for this patient, and recommend an approach.
Read the worked answer
This patient has multiple (6) brain metastases, a large dominant lesion (2.8 cm), a KPS of 60, and mild cognitive impairment. Each option has trade-offs:
- WBRT alone: treats all lesions and micrometastases, but is associated with cognitive decline, especially in patients with limited life expectancy; it is appropriate when the number and size of lesions make SRS impractical or when performance status is poor.
- SRS alone: avoids WBRT-related cognitive toxicity and is preferred for patients with limited brain metastases and good performance status; however, 6 lesions with a 2.8 cm dominant lesion exceeds typical SRS size limits (usually <= 3 cm but with dose reduction) and requires careful dose selection to avoid radionecrosis. SRS alone also risks distant brain failure requiring salvage.
- Hippocampal-avoidance WBRT with memantine: preserves memory function better than standard WBRT and treats all lesions, including micrometastases; it is a reasonable choice for a patient with multiple lesions and a KPS of 60, especially if SRS to all lesions is not feasible.
Recommendation: given the number and size of lesions and the KPS of 60, hippocampal-avoidance WBRT with memantine is a reasonable primary strategy, with a boost to the dominant parietal lesion if tolerated. If the patient's performance status improves and the lesion burden is controlled, SRS could be considered for salvage. Discuss prognosis and goals of care with the family.
2. The family asks whether the largest lesion should be resected or boosted. How do you weigh surgery versus a radiation boost, and what would you tell them?
Read the worked answer
The 2.8 cm left parietal lesion is causing focal symptoms (right-sided weakness). Options for the dominant lesion:
- Surgical resection followed by WBRT or cavity SRS: provides immediate decompression and symptom relief, allows histologic confirmation, and may improve local control; it is most appropriate for a single dominant lesion causing mass effect or neurologic deficit in a patient who can tolerate surgery. This patient has stable extracranial disease and a KPS of 60, so surgery is a reasonable consideration if the lesion is accessible and the patient is a surgical candidate.
- Radiation boost (SRS or fractionated SRT) to the dominant lesion after WBRT: avoids surgery but does not provide immediate decompression; it is appropriate if the lesion is not surgically accessible or the patient prefers to avoid surgery.
Given the mild weakness, the dominant lesion could be considered for surgical resection if the patient is a candidate, followed by WBRT or cavity SRS. If not, hippocampal-avoidance WBRT with a boost to the dominant lesion is reasonable. The family should be told that the goals are symptom control and prevention of neurologic decline, that WBRT treats all lesions, and that the dominant lesion may need additional local treatment. Honest discussion of prognosis and quality of life is essential.